<DOC>
	<DOC>NCT00925587</DOC>
	<brief_summary>The purpose of this study is to determine whether once monthly (QM) dosing of darbepoetin alfa is non-inferior to that of once every 2 week (Q2W) dosing of darbepoetin alfa for the correction of anemia in patients with Chronic Kidney Disease who are not receiving dialysis.</brief_summary>
	<brief_title>Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>≥ 18 years of age Diagnosis of chronic kidney disease with eGFR of 1559 mL/min/1.73 m2 (MDRD equation) Two consecutive screening Hb values taken at least 7 days apart must each be &lt;10.0 g/dL TSAT ≥ 15% Upper or lower GI bleeding within 6 months before enrolment ESA use within 12 weeks before enrolment Uncontrolled hypertension Systemic haematologic disorders Prior history within 12 weeks before enrollment of events including: Acute myocardial ischemia, unstable angina, myocardial infarction, hospitalization for congestive heart failure, stroke or transient ischaemic attack, limb ischaemia, deep vein thrombosis, thromboembolism. Grand mal seizure within 6 months prior to enrolment Evidence of, or received chemotherapy or radiation therapy for, a malignancy within 5 years prior to enrolment. Red blood cell transfusion within 12 weeks prior to enrolment Androgen therapy within 8 weeks prior to enrolment Pregnancy or breast feeding, or inadequate contraception Currently receiving immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>CKD</keyword>
	<keyword>Anemia</keyword>
	<keyword>correction</keyword>
	<keyword>darbepoetin alfa</keyword>
</DOC>